Blog
Information Services Group Sees AI Cloud Demand Fuel Record Tech Spending
Key Points
- Interested in Information Services Group, Inc.? Here are five stocks we like better.
- ISG reported record tech spending in the second quarter, with combined managed services and
Delta Air Lines Q2 Earnings Call Highlights
Key Points
- Interested in Delta Air Lines, Inc.? Here are five stocks we like better.
- Delta posted a strong Q2, with record June-quarter revenue of $17.7 billion, earnings of $1.56 per share
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
Key Points
- Interested in AeroVironment, Inc.? Here are five stocks we like better.
- AeroVironment’s fiscal 2030 targets triggered analyst concern about execution risk, even as management pointed
Micron's $250 Billion Bet Could Reshape the AI Memory Race
Key Points
- Interested in Micron Technology, Inc.? Here are five stocks we like better.
- Micron Technology accelerated its $250 billion domestic fabrication buildout, including a 10-year silicon
Rocket Lab’s Stock Drop Comes With a Bullish Twist
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Rocket Lab stock has dropped nearly 45% from its May peak, yet the company just completed a record-fast Space
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement
Key Points
- Interested in Forte Biosciences, Inc.? Here are five stocks we like better.
- Forte Biosciences said FB102 met its primary endpoint in a small placebo-controlled vitiligo study
MTY Food Group Q2 Earnings Call Highlights
Key Points
- Interested in MTY Food Group Inc.? Here are five stocks we like better.
- MTY Food Group’s second-quarter results weakened as softer consumer traffic, inflation in food costs and
Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Key Points
- Interested in Amazon.com, Inc.? Here are five stocks we like better.
- Amazon is using low-cost debt to help fund a massive artificial intelligence infrastructure buildout.
- Investors are
Broadcom's $30 Billion Apple Deal: This Chip Giant Is About More than Just AI
Key Points
- Interested in Broadcom Inc.? Here are five stocks we like better.
- Broadcom extended its chip supply agreement with Apple through 2031, a deal Apple expects to exceed $30 billion in
eToro Group Unveils AI Trading Push With Tori Agent, New App and Desktop Platform
Key Points
- Interested in eToro Group Ltd.? Here are five stocks we like better.
- eToro unveiled a major AI-driven product overhaul, including a rebuilt mobile app, an expanded AI agent named
Velan Q1 Earnings Call Highlights
Key Points
- Interested in Velan Inc.? Here are five stocks we like better.
- Velan’s Q1 results weakened as bookings fell to $48.0 million from $78.2 million and sales dropped to $57.8 million
IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave
Key Points
- Interested in D-Wave Quantum Inc.? Here are five stocks we like better.
- IQM Quantum Computers began trading on Nasdaq in early July, becoming the first European quantum computing firm
Buyer Beware: These 2 Stocks Charts Just Displayed a Death Cross
Key Points
- Interested in Hertz Global Holdings, Inc.? Here are five stocks we like better.
- Both Hertz Global Holdings and Kinross Gold recently formed death cross patterns, a bearish technical
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Key Points
- Interested in Esperion Therapeutics, Inc.? Here are five stocks we like better.
- Esperion Therapeutics stockholders approved the company’s merger agreement with Essence Parent and
PepsiCo’s Dividend Could Turn Patience Into Real Profit
Key Points
- Interested in PepsiCo, Inc.? Here are five stocks we like better.
- PepsiCo’s Q2 report was mixed, but not weak enough to break the long-term thesis: revenue beat expectations, organic
DeFi Development Doubles Down on Solana Strategy as Crypto Volatility Spurs Cost Cuts
Key Points
- Interested in DeFi Development Corp.? Here are five stocks we like better.
- DeFi Development is tightening costs and shifting more legal and accounting work in-house after a volatile
Schroder Real Estate Invest H2 Earnings Call Highlights
Key Points
- Interested in Schroder Real Estate Invest? Here are five stocks we like better.
- Schroder Real Estate Invest said it remains positioned for earnings growth despite a slight annual
Hays Q4 Earnings Call Highlights
Key Points
- Interested in Hays plc? Here are five stocks we like better.
- Hays reported a 5% like-for-like decline in quarterly net fees, but cost cuts and productivity gains led management to
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
Key Points
- Interested in Catalyst Pharmaceuticals, Inc.? Here are five stocks we like better.
- Catalyst Pharmaceuticals stockholders approved the company’s merger with Angelini Pharma at a
Copart's Incoming CEO Jay Adair Signals Growth Push, M&A and AI Focus
Key Points
- Interested in Copart, Inc.? Here are five stocks we like better.
- Incoming CEO Jay Adair said his return is a long-term move, not interim, and that Copart will accelerate growth
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Key Points
- Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better.
- Compass Pathways said new 26-week Phase 3 COMP006 data support the durability and safety of
Climb Global Solutions Lays Out 2030 Growth Targets, Global M&A Push
Key Points
- Interested in Climb Global Solutions, Inc.? Here are five stocks we like better.
- Climb Global Solutions outlined a long-term plan through 2030 centered on about 10% annual organic
Cerebras Systems, OpenAI Tout $20B AI Compute Deal and Europe Data Center Push
Key Points
- Interested in Cerebras Systems Inc.? Here are five stocks we like better.
- Cerebras and OpenAI said their partnership now includes a compute deal worth more than $20 billion over
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
Key Points
- Interested in Belite Bio, Inc. Sponsored ADR? Here are five stocks we like better.
- Belite Bio says Tinlarebant has completed its Phase 3 DRAGON trial for Stargardt disease, and
AeroVironment Plots Revenue Doubling to $4 Billion on Defense Drone Demand
Key Points
- Interested in AeroVironment, Inc.? Here are five stocks we like better.
- AeroVironment outlined a plan to roughly double revenue to $3.5 billion to $4 billion by fiscal 2030, up from